TC
REGN icon

TradeLink Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

TradeLink Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-200
Closed -$63K – 261
2013
Q3 		$63K Sell
200
-2,600
-93% -$684K 0.14% 172
2013
Q2 		$630K Buy
+2,800
New +$652K 0.19% 85

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TradeLink Capital's REGN Position: Q4 2013 in Review

TradeLink Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2013, closing a stake of 200 shares — an estimated $63K sold.

TradeLink Capital first reported a position in REGN in Q2 2013 and held it in 2 quarters. The position peaked at $630K in Q2 2013. 438 funds tracked by Wall St. Rank hold REGN as of Q4 2013.

  • TradeLink Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • TradeLink Capital sold 200 Regeneron Pharmaceuticals shares in Q4 2013, an estimated $63K.
  • TradeLink Capital first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • TradeLink Capital's Regeneron Pharmaceuticals position peaked at $630K in Q2 2013.
  • 438 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2013.

Based on TradeLink Capital's 13F filing for Q4 2013, filed 6 Feb 2014.